pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 17·1 min read
save

Abridge’s Patient-Centered Claim Scrutinized in STAT AI Prognosis

Jun 17, 2026·read at STAT ↗Negative

Brittany Trang, a health‑tech reporter, wrote a piece for STAT’s AI Prognosis newsletter that takes a close look at Abridge’s assertion that its ambient scribe platform is "patient‑centered."

The article questions whether the claim holds up in practice, situating the discussion within broader concerns about AI’s real‑world impact on patients, clinicians and the healthcare system.

Published as a subscriber‑only feature, the story includes Trang’s background, contact details and a reminder that the newsletter is part of STAT’s premium offering.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Is Abridge’s ‘patient centered’ claim a bridge too far?”

read at STAT ↗
459 words · retrieved Jun 17
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PFIZER

related stories

  • May 6CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineBioPharma Dive
  • May 5Pfizer's Albert Bourla says he has no mega-merger plansEndpoints
  • May 5Pfizer ends Trillium-related development as R&D spend jumpsEndpoints
  • May 5STAT+: Are analysts too quick to gloss over Lilly’s liver case?STAT
  • May 4UCB to acquire maker of antibody treatments for autoimmune diseasesSTAT